Our Mission
SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Early detection at point of care
Nevisense
The Nevisense platform uses advanced technology powerd by AI to empower healthcare professionals by facilitating improved diagnostic accuracy, enabled disease monitoring, and early detection of melanoma at the most curable stage. Its a non-invasive measurement that provides phycisians with objective and actionable data at point-of-care.
News
Events
SciBase partner with a large health care group in Los Angeles, Unified Health, and receives a first order
June 28, 2024STOCKHOLM, SVERIGE, 28 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.
SciBase welcomes new chairman and thanks the former
June 13, 2024STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.
SciBase strengthens the US organization with experienced leader in dermatology
STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces that Leda Beaty has been appointed Head of US Commercial Operations.
Today is the first day of trading in the new shares and warrants of series TO 2 issued in connection with the completed capital raising
May 31, 2024Today, 31 May 2024, trading in the new shares and warrants of series TO 2 begins, which were issued by SciBase Holding AB (publ) ("SciBase" or the "Company") in connection with the capital raising announced by the Company on 5 April 2024, consisting of a rights issue of units of up to approximately SEK 15 million (the "Rights Issue") and a directed issue of units of approximately SEK 33 million (the "Directed Issue" and together with the Rights Issue the "Capital Raising"). The Rights Issue was resolved by the Board of Directors in SciBase on 5 April 2024, pursuant to the authorisation granted by the Annual General Meeting held on 17 May 2023, and the Directed Issue was resolved by the Board of Directors on 5 April 2024, conditional on the subsequent approval by the general meeting. The extraordinary general meeting in the Company on 13 May 2024 resolved to approve the Board of Directors resolution to carry out the Directed Issue.
SciBase receives first order in Austria
May 30, 2024STOCKHOLM, SWEDEN, - May 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce that it has received the first order for a Nevisense system with electrodes in Austria.
SciBase Announces the launch of eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing
May 29, 2024STOCKHOLM, SWEDEN, - May 29, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of artificial intelligence (AI)-based solutions for skin disorders is pleased to announce the launch of the eBarrier Score for Nevisense, the first-ever AI skin barrier assessment tool built for use in research and cosmetic testing. The eBarrier Score was announced today at the Cosmetotest cosmetic testing symposium in Lyon, France.
- Load more news...
News
Our unique platform
Nevisense
The unique Nevisense platform utilizes advanced EIS- technology combined with AI to empower healthcare professionals by improving diagnostic accuracy, enabling disease monitoring, and facilitating early detection of skin cancer. The Nevisense procedure is non-invasive and provides clinicians with objective and actionable data, at point-of-care. It has been developed based on 20+ years of research from the Karolinska Institute and several years of clinical experience.
Lorem ipsum dolor
Lorem ipsum dolor
Integer venenatis sem in orci volutpat, eget placerat est mattis. Vivamus rhoncus leo sed nulla aliquam, id suscipit libero sagittis. Aenean vitae condimentum nisi, ac hendrerit libero.